Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Natera to launch Signatera test in China on BGI's DNBseq NGS platform

Executive Summary

BGI Genomics Co. Ltd. will commercialize in China Natera Inc.'s Signatera minimal residual disease (MRD) and molecular monitoring test. The companies will also partner on the development of reproductive health tests in certain territories.
Deal Industry
  • In Vitro Diagnostics
  • Services
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register